{"id":"eu-approved-keytruda","safety":{"commonSideEffects":[{"rate":"20–30","effect":"Fatigue"},{"rate":"15–25","effect":"Diarrhea"},{"rate":"10–20","effect":"Nausea"},{"rate":"10–15","effect":"Decreased appetite"},{"rate":"3–5","effect":"Immune-mediated pneumonitis"},{"rate":"2–5","effect":"Immune-mediated hepatitis"},{"rate":"2–4","effect":"Immune-mediated colitis"},{"rate":"5–10","effect":"Immune-mediated thyroiditis"},{"rate":"10–15","effect":"Rash"},{"rate":"10–15","effect":"Pruritus"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Keytruda (pembrolizumab) binds to programmed death receptor 1 (PD-1) on T cells, preventing interaction with its ligands PD-L1 and PD-L2 expressed on tumor cells and immune cells. This blockade releases the 'brakes' on the immune system, restoring T cell proliferation, activation, and anti-tumor function. By reinvigorating exhausted T cells, pembrolizumab enables durable anti-tumor immunity across multiple cancer types.","oneSentence":"Keytruda is a monoclonal antibody that blocks PD-1 on immune cells, allowing the immune system to recognize and attack cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:31.989Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma"},{"name":"Non-small cell lung cancer (NSCLC)"},{"name":"Head and neck squamous cell carcinoma"},{"name":"Hodgkin lymphoma"},{"name":"Urothelial carcinoma"},{"name":"Gastric cancer"},{"name":"Cervical cancer"},{"name":"Renal cell carcinoma"},{"name":"Colorectal cancer (microsatellite instability-high or mismatch repair deficient)"}]},"trialDetails":[{"nctId":"NCT06311721","phase":"PHASE3","title":"A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2024-09-09","conditions":"Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer","enrollment":315},{"nctId":"NCT06939595","phase":"PHASE3","title":"A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer","status":"RECRUITING","sponsor":"Celltrion","startDate":"2025-01-30","conditions":"Non Squamous Non Small Cell Lung Cancer","enrollment":606}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"EU-approved Keytruda","genericName":"EU-approved Keytruda","companyName":"Celltrion","companyId":"celltrion","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Keytruda is a monoclonal antibody that blocks PD-1 on immune cells, allowing the immune system to recognize and attack cancer cells. Used for Metastatic melanoma, Non-small cell lung cancer (NSCLC), Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}